Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00546403 · ClinicalTrials.gov registry record · NA

Modafinil Augmentation Therapy for Excessive Daytime Sleepiness and Negative Symptoms in Patients With Schizophrenia

A NA study of Schizophrenia, sponsored by Veterans Medical Research Foundation.

Completed
Registry status
NA
Development phase
26
Enrollment target
1
Study location

NCT00546403 is a NA study of Schizophrenia that has completed, run by Veterans Medical Research Foundation. The registered enrollment target is 26 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00546403, a NA study of Schizophrenia, has completed, sponsored by Veterans Medical Research Foundation.

COMPLETED
Registry status
NA
Development phase
26 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test the effect of modafinil on the negative symptoms, such as blunted affect and social withdrawal, of schizophrenic patients and to determine modafinil's effect on excessive daytime sleepiness. A secondary purpose of the study is to examine the effect of modafinil on cognitive functioning of schizophrenic patients.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Modafinil

Study Locations (1)

California

  • VA Healthcare System, Department of Psychiatry - San Diego

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2003-02
Est. Completion 2008-02
Phase NA

What the Registry Record Tells You About NCT00546403

The ClinicalTrials.gov registry entry for NCT00546403 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (88% lower). The listed sponsor is Veterans Medical Research Foundation, which has 35 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00546403 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00546403 about?

NCT00546403 is a clinical study titled "Modafinil Augmentation Therapy for Excessive Daytime Sleepiness and Negative Symptoms in Patients With Schizophrenia". The purpose of this study is to test the effect of modafinil on the negative symptoms, such as blunted affect and social withdrawal, of schizophrenic patients and to determine modafinil's effect on excessive daytime sleepiness. A secondary purpose of the study is to examine the effect of modafinil o...

What is the current status of trial NCT00546403?

This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2003-02. Estimated completion is 2008-02.

What conditions does trial NCT00546403 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT00546403?

The interventions under investigation include: Placebo (DRUG), Modafinil (DRUG).

Who is sponsoring clinical trial NCT00546403?

This trial is sponsored by Veterans Medical Research Foundation, which has 35 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00546403 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.